• 2181 Citations
  • 20 h-Index
20042020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes

Molga, A., Wall, M., Chhetri, R., Wee, L. Y., Singhal, D., Edwards, S., Singhal, N., Ross, D., To, L. B., Caughey, G., Shakib, S., Germing, U., To, T. & Hiwase, D., 1 Jan 2020, In : Journal of Geriatric Oncology. 11, 1, p. 114-120 7 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., Carne, L., Rwodzi, Z., Watts, S., McLean, J., Braley, J., Altamura, H., Yeung, D. T., Branford, S., Yong, A. S. M., White, D. L., Hughes, T. P. & Ross, D. M., Apr 2020, In : Leukemia. 34, 4, p. 1052-1061 10 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Treatment-free remission in patients with chronic myeloid leukaemia

Ross, D. M. & Hughes, T. P., 1 Aug 2020, In : Nature Reviews Clinical Oncology. 17, 8, p. 493-503 11 p.

Research output: Contribution to journalReview article

Use of romiplostim in pregnancy for refractory idiopathic thrombocytopenic purpura: Two case reports with maternal and fetal outcomes and literature review

Chua, S. J., Morton, M. R., Svigos, J., Ross, D. M. & Kane, S., 1 Mar 2020, In : Obstetric Medicine. 13, 1, p. 45-50 6 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)
2019

Asciminib in chronic myeloid leukemia after Abl kinase inhibitor failure

Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y. T., Talpaz, M., Hochhaus, A., Coutre, P. L., Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F. X., Minami, Y., Yeung, D., Ross, D. M. & 10 others, Tallman, M. S., Park, J. H., Druker, B. J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K. G., Lang, F. & Kim, D. W., 12 Dec 2019, In : New England Journal of Medicine. 381, 24, p. 2315-2326 12 p.

Research output: Contribution to journalArticle

20 Citations (Scopus)

Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014

Baade, P. D., Ross, D. M., Anderson, L. A., Forsyth, C. & Fritschi, L., Apr 2019, In : American Journal of Hematology. 94, 4, p. E107-E109

Research output: Contribution to journalLetter

2 Citations (Scopus)

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Ross, D. M., Pagani, I., Irani, Y., Clarson, J., Gray, T., Dang, Y., McLean, J., Saunders, V., Carne, L., Reynolds, J., Ritchie, D. S., White, D., Branford, S., Hughes, T. & Yong, A., 1 Aug 2019, In : British Journal of Haematology. 186, 3, p. e56-e60

Research output: Contribution to journalLetter

4 Citations (Scopus)
5 Citations (Scopus)

Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms

Forsyth, C. J., Chan, W. H., Grigg, A. P., Cook, N. C., Lane, S. W., Burbury, K. L., Perkins, A. C. & Ross, D. M., 1 Aug 2019, In : Internal Medicine Journal. 49, 8, p. 948-954 7 p.

Research output: Contribution to journalReview article

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

Lasica, M., Willcox, A., Burbury, K., Ross, D. M., Branford, S., Butler, J., Filshie, R., Januszewicz, H., Joske, D., Mills, A., Simpson, D., Tam, C., Taylor, K., Watson, A. M., Wolf, M. & Grigg, A., 7 Jun 2019, In : Leukemia and Lymphoma. 60, 7, p. 1796-1802 7 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)
2018

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., Kan, W. L., Hercus, T. R., Stomski, F., Hughes, T., Tergaonkar, V., Parker, M. W., Ross, D. M., Majeti, R., Babon, J. J. & Lopez, A. F., 28 Nov 2018, In : Science Advances. 4, 11, eaat3834.

Research output: Contribution to journalArticle

7 Citations (Scopus)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., Braley, J., White, D. L., Yeung, D. T., Branford, S., Hughes, T. P. & Ross, D. M., 30 Nov 2018, In : Haematologica. 103, 12, p. 2026-2032 7 p.

Research output: Contribution to journalArticle

Open Access
13 Citations (Scopus)

Chronic myeloid leukaemia: going off piste

Ross, D., 1 Jun 2018, In : The Lancet Oncology. 19, 6, p. 717-718 2 p.

Research output: Contribution to journalComment/debate

Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

Ross, D., Arthur, C., Burbury, K., Ko, B. S., Mills, A. K., Shortt, J. & Kostner, K., 1 Feb 2018, In : Internal Medicine Journal. 48, p. 5-13 9 p.

Research output: Contribution to journalReview article

8 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., 1 May 2018, In : Journal of Cancer Research and Clinical Oncology. 144, 5, p. 945-954 10 p.

Research output: Contribution to journalArticle

43 Citations (Scopus)

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Branford, S., Wang, P., Yeung, D., Thomson, D., Purins, A., Wadham, C., Shahrin, N. H., Marum, J. E., Nataren, N., Parker, W. T., Geoghegan, J., Feng, J., Shanmuganathan, N., Mueller, M. C., Dietz, C., Stangl, D., Donaldson, Z., Altamura, H., Georgievski, J., Braley, J. & 13 others, Brown, A., Hahn, C., Walker, I., Kim, S. H., Choi, S. Y., Park, S. H., Kim, D. W., White, D., Yong, A., Ross, D. M., Scott, H. S., Schreiber, A. W. & Hughes, T., 30 Aug 2018, In : Blood. 132, 9, p. 948-961 14 p.

Research output: Contribution to journalArticle

35 Citations (Scopus)

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG), 1 Dec 2018, In : Leukemia. 32, 12, p. 2572-2579 8 p.

Research output: Contribution to journalArticle

14 Citations (Scopus)

Management of pregnancy in women with chronic myeloid leukemia

Ross, D. M., Burbury, K. L., Grigg, A. P., Hughes, T. & Seymour, J. F., 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2657-2658 2 p.

Research output: Contribution to journalLetter

2 Citations (Scopus)

Patient perceptions of treatment-free remission in chronic myeloid leukemia

Villemagne Sanchez, L. A., O’Callaghan, C., Gough, K., Hall, K., Kashima, Y., Seymour, J. F., Schofield, P. & Ross, D., 1 Feb 2018, In : Leukemia and Lymphoma. 59, 2, p. 406-415 10 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)

Success is built on failures: tackling the challenge of ponatinib failure

Hiwase, D. & Ross, D., 3 Jun 2018, In : Leukemia and Lymphoma. 59, 6, p. 1279-1281 3 p.

Research output: Contribution to journalComment/debate

1 Citation (Scopus)
2017

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis

Ho, P. J., Bajel, A., Burbury, K., Dunlop, L., Durrant, S., Forsyth, C., Perkins, A. C. & Ross, D. M., 1 Mar 2017, In : Internal Medicine Journal. 47, 3, p. 262-268 7 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm

Casolari, D. A., Nguyen, T., Butcher, C. M., Iarossi, D. G., Hahn, C. N., Bray, S. C., Neufing, P. J., Parker, W. T., Feng, J., Maung, K. Z. Y., Wee, A., Vidovic, L., Kok, C. H., Bardy, P. G., Branford, S., Lewis, I. D., Lane, S. W., Scott, H. S., Ross, D. M. & D'Andrea, R. J., 1 Dec 2017, In : Scientific Reports. 7, 1, 2467.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Apparent ‘JAK2-negative’ polycythaemia vera due to compound mutations in exon 14

Tiong, I. S., Casolari, D. A., Moore, S., Nguyen, T., Van Velzen, M. J. M., Zantomio, D., Scott, H. S., D'Andrea, R. J., Hahn, C. N. & Ross, D., Jul 2017, In : British Journal of Haematology. 178, 2, p. 333-336 4 p.

Research output: Contribution to journalLetter

4 Citations (Scopus)

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

Douglas, G., Harrison, C., Forsyth, C., Bennett, M., Stevenson, W., Hounsell, J., Ratnasingam, S., Ritchie, D., Ross, D. M. & Grigg, A., 2 Jan 2017, In : Leukemia and Lymphoma. 58, 1, p. 89-95 7 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients

Hiwase, D., Singhal, D., Strupp, C., Chhetri, R., Kutyna, M. M., Wee, L. A., Harrison, P. B., Nath, S. V., Wickham, N., Hui, C. H., Gray, J. X., Bardy, P., Ross, D. M., Lewis, I. D., Reynolds, J., To, L. B. & Germing, U., 1 Jun 2017, In : American Journal of Hematology. 92, 6, p. 508-514 7 p.

Research output: Contribution to journalArticle

11 Citations (Scopus)

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome

Singhal, D., Kutyna, M. M., Chhetri, R., Wee, L. Y. A., Hague, S., Nath, L., Nath, S. V., Sinha, R., Wickham, N., Lewis, I. D., Ross, D. M., Bardy, P. G., To, L. B., Reynolds, J., Wood, E. M., Roxby, D. J. & Hiwase, D., 30 Nov 2017, In : Haematologica. 102, 12, p. 2021-2029 9 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)

Responses to pomalidomide and placebo in myelofibrosis-related anaemia

Ross, D., 1 Mar 2017, In : Leukemia. 31, 3, p. 532-533 2 p.

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR

Kommers, I. O., Bartley, P. A., Budgen, B., Latham, S., Beligaswatte, A., Supple, S. G., Catalano, A., Iland, H. J., Morley, A. A. & Ross, D., 3 Jul 2017, In : Leukemia and Lymphoma. 58, 7, p. 1767-1769 3 p.

Research output: Contribution to journalLetter

4 Citations (Scopus)

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1

Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., Buonamici, S., Hassan, A. Q., Lombardo, F., Iyer, V., Palmer, M., Berellini, G., Dodd, S., Thohan, S., Bitter, H., Branford, S. & 8 others, Ross, D. M., Hughes, T. P., Petruzzelli, L., Vanasse, K. G., Warmuth, M., Hofmann, F., Keen, N. J. & Sellers, W. R., 30 Mar 2017, In : Nature. 543, 7647, p. 733-737 5 p.

Research output: Contribution to journalArticle

153 Citations (Scopus)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study

Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V., Gattermann, N., Wiktor-Jedrzejczak, W., Le Coutre, P. D., Martino, B., Saussele, S., Menssen, H. D., Deng, W., Krunic, N., Bedoucha, V. & Saglio, G., 1 Jul 2017, In : Leukemia. 31, 7, p. 1525-1531 7 p.

Research output: Contribution to journalArticle

122 Citations (Scopus)

Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome

Shanmuganathan, N., Hiwase, D. K. & Ross, D. M., 2 Dec 2017, In : Leukemia and Lymphoma. 58, 12, p. 2799-2810 12 p.

Research output: Contribution to journalReview article

5 Citations (Scopus)
2016

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia

Latham, S., Bartley, P. A., Budgen, B., Ross, D. M., Hughes, E., Branford, S., White, D., Hughes, T. P. & Morley, A. A., Sep 2016, In : Journal of Clinical Pathology. 69, 9, p. 817-821 5 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene

Ross, D. M., Altamura, H. K., Hahn, C. N., Nicola, M., Yeoman, A. L., Holloway, M. R., Geoghegan, J., Feng, J., Schreiber, A. W., Branford, S., Moore, S. & Scott, H. S., 1 Jun 2016, In : Leukemia. 30, 6, p. 1402-1405 4 p.

Research output: Contribution to journalLetter

4 Citations (Scopus)

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera

Tiong, I. S., Casolari, D. A., Nguyen, T., Van Velzen, M. J. M., Ambler, K., D'Andrea, R. J. & Ross, D., 19 Aug 2016, In : Blood cancer journal. 6, 8, p. e459

Research output: Contribution to journalLetter

2 Citations (Scopus)

Moving treatment-free remission into mainstream clinical practice in CML

Hughes, T. P. & Ross, D. M., 7 Jul 2016, In : Blood. 128, 1, p. 17-23 7 p.

Research output: Contribution to journalReview article

179 Citations (Scopus)

Novel protein C gene mutation in a compound heterozygote resulting in catastrophic thrombosis in early adulthood: Diagnosis and long-term treatment with subcutaneous protein C concentrate

Boey, J. P., Jolley, A., Nicholls, C., Lerda, N., Duncan, E., Gallus, A., Ross, D. & Sobieraj-Teague, M., 1 Mar 2016, In : British Journal of Haematology. 172, 5, p. 811-813 3 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)
2015

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia

Bartley, P. A., Latham, S., Budgen, B., Ross, D. M., Hughes, E., Branford, S., White, D., Hughes, T. P. & Morley, A. A., 1 Jan 2015, In : Journal of Molecular Diagnostics. 17, 2, p. 185-192 8 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)

A tale of two siblings: Two cases of AML arising from a single pre-leukemic DNMT3A mutant clone

Hahn, C. N., Ross, D. M., Feng, J., Beligaswatte, A., Hiwase, D., Parker, W. T., Ho, M., Zawitkowski, M., Ambler, K. L., Cheetham, G. D., Lee, Y. K., Babic, M., Butcher, C. M., Engler, G. A., Brown, A. L., D'Andrea, R. J., Lewis, I. D., Schreiber, A. W., To, L. B. & Scott, H. S., 1 Oct 2015, In : Leukemia. 29, 10, p. 2101-2104 4 p.

Research output: Contribution to journalLetter

19 Citations (Scopus)

Discontinuation of therapy and treatment-free remission in CML

Ross, D. M. & Hughes, T., 1 Jan 2015, Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. Springer Japan, p. 183-193 11 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Practical management of myelofibrosis with ruxolitinib

Ho, P. J., Marlton, P., Tam, C., Stevenson, W., Ritchie, D., Bird, R., Dunlop, L. C., Durrant, S. & Ross, D. M., 1 Dec 2015, In : Internal Medicine Journal. 45, 12, p. 1221-1230 10 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

TIDEL-Ii: First-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Braley, J., Herschtal, A., Kornhauser, M., Issa, S., Hiwase, D. K., Hertzberg, M., Schwarer, A. P., Filshie, R., Arthur, C. K., Kwan, Y. L., Trotman, J., Forsyth, C. J., Taper, J., Ross, D. M., Beresford, J., Tam, C. & 3 others, Mills, A. K., Grigg, A. P. & Hughes, T. P., 5 Feb 2015, In : Blood. 125, 6, p. 915-923 9 p.

Research output: Contribution to journalArticle

62 Citations (Scopus)

Treatment-free remission after stopping second-line dasatinib

Ross, D. M., 1 Dec 2015, In : The Lancet Haematology. 2, 12, p. e506-e507

Research output: Contribution to journalComment/debate

Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia

Hotinski, A. K., Lewis, I. D. & Ross, D. M., 1 Jun 2015, In : Expert Opinion on Pharmacotherapy. 16, 9, p. 1395-1402 8 p.

Research output: Contribution to journalReview article

15 Citations (Scopus)
2014
36 Citations (Scopus)

Need to minimize bias when surveying patient attitudes to stopping cml treatment

Villemagne-Sanchez, L. A., Ross, D. & Schofield, P., 1 Jan 2014, In : Current Oncology. 21, 6

Research output: Contribution to journalLetter

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Cheah, C. Y., Burbury, K., Apperley, J. F., Huguet, F., Pitini, V., Gardembas, M., Ross, D. M., Forrest, D., Genet, P., Rousselot, P., Patton, N., Smith, G., Dunbar, C. E., Ito, S., Aguiar, R. C. T., Odenike, O., Gimelfarb, A., Cross, N. C. P. & Seymour, J. F., 5 Jun 2014, In : Blood. 123, 23, p. 3574-3577 4 p.

Research output: Contribution to journalArticle

72 Citations (Scopus)

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Branford, S., Yeung, D. T., Parker, W. T., Roberts, N. D., Purins, L., Braley, J. A., Altamura, H. K., Yeoman, A. L., Georgievski, J., Jamison, B. A., Phillis, S., Donaldson, Z., Leong, M., Fletcher, L., Seymour, J. F., Grigg, A. P., Ross, D. M. & Hughes, T. P., 24 Jul 2014, In : Blood. 124, 4, p. 511-518 8 p.

Research output: Contribution to journalArticle

125 Citations (Scopus)